Tebentafusp (IMCgp100) is a bispecific fusion protein designed to specifically target the gp100 peptide-HLA-A*02:01 complex, an antigen commonly associated with melanoma. This innovative therapeutic agent employs a dual-action mechanism: it features a high-affinity T-cell receptor (TCR) binding domain that recognizes and binds to gp100-expressing tumor cells, coupled with an anti-CD3 T-cell engaging domain that recruits and activates T cells. Upon engagement, Tebentafusp mediates the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells. This targeted approach not only enhances the specificity of T-cell mediated tumor cell killing but also minimizes off-target effects, making it a promising candidate for melanoma therapy.
Tebentafusp (IMCgp100) is a bispecific fusion protein designed to specifically target the gp100 peptide-HLA-A*02:01 complex, an antigen commonly associated with melanoma. This innovative therapeutic agent employs a dual-action mechanism: it features a high-affinity T-cell receptor (TCR) binding domain that recognizes and binds to gp100-expressing tumor cells, coupled with an anti-CD3 T-cell engaging domain that recruits and activates T cells. Upon engagement, Tebentafusp mediates the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells. This targeted approach not only enhances the specificity of T-cell mediated tumor cell killing but also minimizes off-target effects, making it a promising candidate for melanoma therapy.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
